董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mara G. Aspinall | 女 | Director | 56 | 4.60万美元 | 未持股 | 2019-06-30 |
| David Kabakoff | 女 | Director | 71 | 未披露 | 未持股 | 2019-06-30 |
| Joseph C. Cook III | 男 | Director | 48 | 未披露 | 未持股 | 2019-06-30 |
| Derek J. Maetzold | 男 | President, Chief Executive Officer and Director | 57 | 79.08万美元 | 未持股 | 2019-06-30 |
| Daniel M. Bradbury | 男 | Chairman of the Board of Director | 58 | 未披露 | 未持股 | 2019-06-30 |
| G. Bradley Cole | 男 | Director | 63 | 未披露 | 未持股 | 2019-06-30 |
| Bonnie H. Anderson | 女 | Director | 61 | 2.00万美元 | 未持股 | 2019-06-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Federico A. Monzon | 男 | Chief Medical Officer | 51 | 47.39万美元 | 未持股 | 2019-06-30 |
| Bernhard E. Spiess | 男 | Chief Operating Officer | 59 | 未披露 | 未持股 | 2019-06-30 |
| Frank Stokes | 男 | Chief Financial Officer | 49 | 54.86万美元 | 未持股 | 2019-06-30 |
| Derek J. Maetzold | 男 | President, Chief Executive Officer and Director | 57 | 79.08万美元 | 未持股 | 2019-06-30 |
董事简历
中英对照 | 中文 | 英文- Mara G. Aspinall
-
Mara G. Aspinall， 担任Ventana Medical Systems的总裁兼首席执行官、Roche Tissue Diagnostics（一个开发、生产和商业化组织的癌症诊断设备和产品的领导者）的全球主管、On-Q-ity, Inc.（研究公司，专注于改变癌症病人的管理）的创始人、首席执行官和董事（2009年9月至2011年5月）、Genzyme Corporation的多种领导职务，其中包括Genzyme Genetics总裁、Genzyme Pharmaceuticals（美国深奥的基因测试的领先供应商，专注于生殖、肿瘤学和个性化医疗市场）的总裁（1997年6月至2009年8月）。
Mara G. Aspinall joined the Board in June 2017. Since 2014 she has served as the Managing Member of Health Catalysts Group, a consulting firm that focuses on growth of life science and technology companies. Ms. Aspinall has also served as Managing Director of BlueStone Venture Partners, a venture capital firm dedicated to investing in life sciences and healthcare related companies. Prior to these positions, Ms. Aspinall served as President and CEO, Global Head of Roche Tissue Diagnostics/Ventana Medical Systems, a division of The Roche Group that provides tissue-based cancer diagnostic instruments, products and services. Prior to that, she founded and served as CEO and Director of On-Q-ity, Inc., a diagnostic research company focused on improving cancer treatment through the capture of circulating tumor cells in a patient’s blood. Ms. Aspinall also spent 12 years with Genzyme Corporation, serving as President of the Genzyme Genetics division, a leading provider of esoteric and genetic tests for the reproductive, oncology and personalized medicine markets, and as President of the Genzyme Pharmaceuticals division, a custom pharmaceutical intermediates provider. Ms. Aspinall began her career as a management consultant with Bain & Company. Ms. Aspinall holds an M.B.A. from Harvard Business School and a B.A. in International Relations from Tufts University. Ms. Aspinall is certified in Cybersecurity Oversight from Carnegie Mellon University. Ms. Aspinall previously served on the Board at Safeguard Scientific and currently serves on the Boards of Castle Biosciences, Inc., Abcam Plc, Allscripts Healthcare Solutions, Inc. and DA32 Life Sciences Acquisition Corp. - Mara G. Aspinall， 担任Ventana Medical Systems的总裁兼首席执行官、Roche Tissue Diagnostics（一个开发、生产和商业化组织的癌症诊断设备和产品的领导者）的全球主管、On-Q-ity, Inc.（研究公司，专注于改变癌症病人的管理）的创始人、首席执行官和董事（2009年9月至2011年5月）、Genzyme Corporation的多种领导职务，其中包括Genzyme Genetics总裁、Genzyme Pharmaceuticals（美国深奥的基因测试的领先供应商，专注于生殖、肿瘤学和个性化医疗市场）的总裁（1997年6月至2009年8月）。
- Mara G. Aspinall joined the Board in June 2017. Since 2014 she has served as the Managing Member of Health Catalysts Group, a consulting firm that focuses on growth of life science and technology companies. Ms. Aspinall has also served as Managing Director of BlueStone Venture Partners, a venture capital firm dedicated to investing in life sciences and healthcare related companies. Prior to these positions, Ms. Aspinall served as President and CEO, Global Head of Roche Tissue Diagnostics/Ventana Medical Systems, a division of The Roche Group that provides tissue-based cancer diagnostic instruments, products and services. Prior to that, she founded and served as CEO and Director of On-Q-ity, Inc., a diagnostic research company focused on improving cancer treatment through the capture of circulating tumor cells in a patient’s blood. Ms. Aspinall also spent 12 years with Genzyme Corporation, serving as President of the Genzyme Genetics division, a leading provider of esoteric and genetic tests for the reproductive, oncology and personalized medicine markets, and as President of the Genzyme Pharmaceuticals division, a custom pharmaceutical intermediates provider. Ms. Aspinall began her career as a management consultant with Bain & Company. Ms. Aspinall holds an M.B.A. from Harvard Business School and a B.A. in International Relations from Tufts University. Ms. Aspinall is certified in Cybersecurity Oversight from Carnegie Mellon University. Ms. Aspinall previously served on the Board at Safeguard Scientific and currently serves on the Boards of Castle Biosciences, Inc., Abcam Plc, Allscripts Healthcare Solutions, Inc. and DA32 Life Sciences Acquisition Corp.
- David Kabakoff
-
David Kabakoff自2017年9月以来一直担任我们的董事会成员。自2012年以来，Kabakoff博士担任HealthQuest Capital的合伙人。自2007年以来，Kabakoff博士还担任Sofinnova Ventures的执行合伙人。Kabakoff博士目前担任NextCure，Inc.公司的董事会主席，该公司是一家公开上市的生物制药公司。Kabakoff博士还担任许多私人公司的董事会成员，包括生物制药公司Antiva Biosciences，Inc.，生物制药公司Daunless Pharmaceuticals，基因检测公司Lineagen董事长，分子诊断公司Biotheranostics，生物制药公司Rainier Therapeutics，Inc.和生物制药公司Neurana Pharmaceuticals，Inc.。从2006年到2014年10月，Kabakoff博士担任Intermune Inc.的董事，该公司是一家公开上市的生物制药公司。2001年，Kabakoff博士共同创立了SalMedix，Inc.，该公司是一家癌症药物治疗的开发商，曾担任其董事长兼首席执行官，并于2005年6月领导该公司被生物制药公司Cephalon，Inc.收购。从1996年到2000年，Kabakoff博士担任Dura Pharmaceuticals，Inc.的执行Vice President和Spiros的总裁兼首席执行官，这两家公司都是制药公司。Kabakoff从1989年到1996年担任Corvas International，Inc.（一家生物疗法开发商）首席执行官，从1983年到1989年担任Hybritech（一家生物技术公司）高级执行职位。Kabakoff博士拥有凯斯西储大学（Case Western Reserve University）的化学学士学位和耶鲁大学（Yale University）的博士学位。
David Kabakoff,has served as Executive Partner at Sofinnova Investments, Inc., a clinical-stage biopharmaceutical venture capital firm, since May 2007 and became a founding Partner of HealthQuest Capital, a health care innovation venture capital firm, in 2012. Dr. Kabakoff currently serves on the board of directors of the privately-held life sciences company RareCyte, Inc. Dr. Kabakoff previously served as a director of several other publicly traded and privately held life sciences companies, including Castle Biosciences, Inc. from September 2017 to August 2021, Principia Biopharma, Inc. from June 2016 to August 2018 in advance of Principia's September 2018 initial public offering, publicly traded lnterMune, Inc. from November 2005 to September 2014, and Amplimmune from 2007 until its acquisition by AstraZeneca plc in October 2013. In 2001, Dr. Kabakoff co-founded Salmedix, Inc., a company that developed cancer drug treatments, served as the company's Chairman and Chief Executive Officer and led its acquisition in June 2005 by Cephalon, Inc. Previously, Dr. Kabakoff served as Executive Vice President of Dura Pharmaceuticals, Inc., a pharmaceutical company, as President and Chief Executive Officer of Spiros, a pharmaceutical company, as Chief Executive Officer of Corvas International, Inc., a developer of biotherapeutics, and in senior executive positions with Hybritech, a biotechnology company. Dr. Kabakoff received a B.A. in chemistry from Case Western Reserve University and a Ph.D. in chemistry from Yale University. - David Kabakoff自2017年9月以来一直担任我们的董事会成员。自2012年以来，Kabakoff博士担任HealthQuest Capital的合伙人。自2007年以来，Kabakoff博士还担任Sofinnova Ventures的执行合伙人。Kabakoff博士目前担任NextCure，Inc.公司的董事会主席，该公司是一家公开上市的生物制药公司。Kabakoff博士还担任许多私人公司的董事会成员，包括生物制药公司Antiva Biosciences，Inc.，生物制药公司Daunless Pharmaceuticals，基因检测公司Lineagen董事长，分子诊断公司Biotheranostics，生物制药公司Rainier Therapeutics，Inc.和生物制药公司Neurana Pharmaceuticals，Inc.。从2006年到2014年10月，Kabakoff博士担任Intermune Inc.的董事，该公司是一家公开上市的生物制药公司。2001年，Kabakoff博士共同创立了SalMedix，Inc.，该公司是一家癌症药物治疗的开发商，曾担任其董事长兼首席执行官，并于2005年6月领导该公司被生物制药公司Cephalon，Inc.收购。从1996年到2000年，Kabakoff博士担任Dura Pharmaceuticals，Inc.的执行Vice President和Spiros的总裁兼首席执行官，这两家公司都是制药公司。Kabakoff从1989年到1996年担任Corvas International，Inc.（一家生物疗法开发商）首席执行官，从1983年到1989年担任Hybritech（一家生物技术公司）高级执行职位。Kabakoff博士拥有凯斯西储大学（Case Western Reserve University）的化学学士学位和耶鲁大学（Yale University）的博士学位。
- David Kabakoff,has served as Executive Partner at Sofinnova Investments, Inc., a clinical-stage biopharmaceutical venture capital firm, since May 2007 and became a founding Partner of HealthQuest Capital, a health care innovation venture capital firm, in 2012. Dr. Kabakoff currently serves on the board of directors of the privately-held life sciences company RareCyte, Inc. Dr. Kabakoff previously served as a director of several other publicly traded and privately held life sciences companies, including Castle Biosciences, Inc. from September 2017 to August 2021, Principia Biopharma, Inc. from June 2016 to August 2018 in advance of Principia's September 2018 initial public offering, publicly traded lnterMune, Inc. from November 2005 to September 2014, and Amplimmune from 2007 until its acquisition by AstraZeneca plc in October 2013. In 2001, Dr. Kabakoff co-founded Salmedix, Inc., a company that developed cancer drug treatments, served as the company's Chairman and Chief Executive Officer and led its acquisition in June 2005 by Cephalon, Inc. Previously, Dr. Kabakoff served as Executive Vice President of Dura Pharmaceuticals, Inc., a pharmaceutical company, as President and Chief Executive Officer of Spiros, a pharmaceutical company, as Chief Executive Officer of Corvas International, Inc., a developer of biotherapeutics, and in senior executive positions with Hybritech, a biotechnology company. Dr. Kabakoff received a B.A. in chemistry from Case Western Reserve University and a Ph.D. in chemistry from Yale University.
- Joseph C. Cook III
-
JosephC.Cook III自2018年8月以来一直担任我们的董事会成员。Cook自2003年2月起担任Mountain Group Partners（一家投资公司，投资于生命科学、农业科技和技术领域）总经理。从2001年1月到2003年2月，Cook先生担任Robert W.Baird&Co.投资银行集团的私募董事。合并。库克此前还曾担任J.C.Bradford&Co.投资银行集团的Vice President。Cook先生任职于Mindera Corp.（一家无创转录组测试公司）和CabeTech Medical Systems，Inc.（一家机器学习大脑诊断公司）的董事会。Cook先生持有Davidson College经济学学士学位。
Joseph C. Cook III has served as a member of our board of directors since August 2018. Since February 2003 Mr. Cook has served as a Managing Director at Mountain Group Partners, an investment firm with investments in the Life Sciences, AgTech and Technology sectors. From January 2001 until February 2003 Mr. Cook served as a Director, Private Placements in the Investment Banking Group of Robert W. Baird & Co. Incorporated. Mr. Cook also previously served as a Vice President in the Investment Banking Group at J.C. Bradford & Co. Mr. Cook serves on the board of directors of MiNDERA Corp., a non-invasive transcriptome testing company, and Cerebrotech Medical Systems, Inc., a machine learning cerebral diagnostic company. Mr. Cook holds a B.A. degree in Economics from Davidson College. - JosephC.Cook III自2018年8月以来一直担任我们的董事会成员。Cook自2003年2月起担任Mountain Group Partners（一家投资公司，投资于生命科学、农业科技和技术领域）总经理。从2001年1月到2003年2月，Cook先生担任Robert W.Baird&Co.投资银行集团的私募董事。合并。库克此前还曾担任J.C.Bradford&Co.投资银行集团的Vice President。Cook先生任职于Mindera Corp.（一家无创转录组测试公司）和CabeTech Medical Systems，Inc.（一家机器学习大脑诊断公司）的董事会。Cook先生持有Davidson College经济学学士学位。
- Joseph C. Cook III has served as a member of our board of directors since August 2018. Since February 2003 Mr. Cook has served as a Managing Director at Mountain Group Partners, an investment firm with investments in the Life Sciences, AgTech and Technology sectors. From January 2001 until February 2003 Mr. Cook served as a Director, Private Placements in the Investment Banking Group of Robert W. Baird & Co. Incorporated. Mr. Cook also previously served as a Vice President in the Investment Banking Group at J.C. Bradford & Co. Mr. Cook serves on the board of directors of MiNDERA Corp., a non-invasive transcriptome testing company, and Cerebrotech Medical Systems, Inc., a machine learning cerebral diagnostic company. Mr. Cook holds a B.A. degree in Economics from Davidson College.
- Derek J. Maetzold
-
DerekJ.Maetzold于2007年9月创立了Castle Biosciences，自成立以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。此前，Maetzold先生曾在Encysive Pharmaceuticals、Schering-PloughCorporation（现为默克公司）、Integrated Communications、Amylin Pharmaceuticals和Sandoz Pharmaceuticals（现为诺华公司的一个部门）担任领导职务。Maetzold先生目前担任Ocular Melanoma Foundation的董事。他为癌症的五种诊断和预后测试的发现、开发和商业化做出了贡献，共同撰写了多个科学出版物，是Castle Biosciences和Encysive Pharmaceuticals多项技术的共同发明人。Maetzold先生拥有乔治梅森大学（George Mason University）的生物学B.S.学位，并完成了卡尔加里大学健康科学中心（University of Calgary Health Sciences Center）的额外课程和加州大学河滨分校（University of California，Riverside）的工商管理硕士课程。
Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President and Chief Executive Officer and as a member of our board of directors since inception. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation now Merck, Integrated Communications, Amylin Pharmaceuticals and Sandoz Pharmaceuticals (now a division of Novartis). Mr. Maetzold currently serves as a director of the Ocular Melanoma Foundation. He has contributed to the discovery, development and commercialization of five diagnostic and prognostic tests in cancers, has co-authored multiple scientific publications and is a co-inventor of a number of technologies at Castle Biosciences and Encysive Pharmaceuticals. Mr. Maetzold holds a B.S. degree in Biology from George Mason University and completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at the University of California, Riverside. - DerekJ.Maetzold于2007年9月创立了Castle Biosciences，自成立以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。此前，Maetzold先生曾在Encysive Pharmaceuticals、Schering-PloughCorporation（现为默克公司）、Integrated Communications、Amylin Pharmaceuticals和Sandoz Pharmaceuticals（现为诺华公司的一个部门）担任领导职务。Maetzold先生目前担任Ocular Melanoma Foundation的董事。他为癌症的五种诊断和预后测试的发现、开发和商业化做出了贡献，共同撰写了多个科学出版物，是Castle Biosciences和Encysive Pharmaceuticals多项技术的共同发明人。Maetzold先生拥有乔治梅森大学（George Mason University）的生物学B.S.学位，并完成了卡尔加里大学健康科学中心（University of Calgary Health Sciences Center）的额外课程和加州大学河滨分校（University of California，Riverside）的工商管理硕士课程。
- Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President and Chief Executive Officer and as a member of our board of directors since inception. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation now Merck, Integrated Communications, Amylin Pharmaceuticals and Sandoz Pharmaceuticals (now a division of Novartis). Mr. Maetzold currently serves as a director of the Ocular Melanoma Foundation. He has contributed to the discovery, development and commercialization of five diagnostic and prognostic tests in cancers, has co-authored multiple scientific publications and is a co-inventor of a number of technologies at Castle Biosciences and Encysive Pharmaceuticals. Mr. Maetzold holds a B.S. degree in Biology from George Mason University and completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at the University of California, Riverside.
- Daniel M. Bradbury
-
Daniel M. Bradbury，自2020年1月起担任董事会执行主席，自2017年3月起担任董事会成员。他于2018年6月至2019年12月担任首席执行官。Bradbury先生是Equillium的联合创始人，并于2017年3月至2018年6月担任总裁。他是BioBrit， LLC（生命科学咨询和投资公司）的创始人和管理成员（2012年9月以来）。2007年3月至2012年8月Amylin被百时美施贵宝公司（Bristol-Myers Squibb company）收购，他担任Amylin Pharmaceuticals， Inc.（一家上市的生物制药公司）的总裁、首席执行官和董事。Bradbury先生自2019年7月起担任Castle Biosciences， Inc 。的董事会成员，他还担任薪酬委员会成员和董事会主席。他自2019年1月起担任Biocon Biologics Ltd.的董事会成员，并担任审计委员会成员。他自2024年3月起担任Vivani Medical， Inc.的董事会成员，在那里他还担任审计委员会成员。此外，他还担任许多私人公司的董事会成员。他曾担任Intercept Pharmaceuticals， Inc.（一家上市的生物技术公司）的董事会成员（从2016年到2023年）；Biocon Ltd.，一家上市的生物制药公司，从2013年到2022年；concept Therapeutics Incorporated，一家上市的生物技术公司，从2012年到2019年；Geron Corporation，一家上市的生物技术公司，从2012年到2019年；Illumina, Inc.（一家上市的生物技术公司），从2004年到2017年；Panacea Acquisition Corporation（一家上市的特殊目的收购公司），从2020年到2021年。他持有Nottingham大学的药学学士学位，以及Harrow and Ealing Colleges of Higher Education的管理学文凭。
Daniel M. Bradbury,has served as the Executive Chairman of Board since January 2020 and has been a member of Board since March 2017. He served as Chief Executive Officer from June 2018 through December 2019. Mr. Bradbury is a co-founder of Equillium and served as President from March 2017 until June 2018. Mr. Bradbury is the founder and has served as the managing member of BioBrit, LLC ("BioBrit"), a life science consulting and investment firm, since September 2012. Mr. Bradbury served as President, Chief Executive Officer and a director of Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from March 2007 until Amylin's acquisition by Bristol-Myers Squibb Company in August 2012. Mr. Bradbury has served on the board of directors of Castle Biosciences, Inc since July 2019, where he also serves on the compensation committee and as chairman of the board. He has served on the board of directors of Biocon Biologics Ltd. since January 2019, where he also serves on the audit committee. He has served on the board of directors of Vivani Medical, Inc. since March 2024, where he also serves on the audit committee.Additionally, Mr. Bradbury serves on the boards of many private companies. Mr. Bradbury previously served on the boards of directors of Intercept Pharmaceuticals, Inc., a publicly-held biotechnology company, from 2016 to 2023; Biocon Ltd., a publicly-held biopharmaceutical company, from 2013 to 2022; Corcept Therapeutics Incorporated, a publicly-held biotechnology company, from 2012 to 2019; Geron Corporation, a publicly-held biotechnology company, from 2012 to 2019; Illumina, Inc., a publicly-held biotechnology company, from 2004 to 2017; and Panacea Acquisition Corporation, a publicly-held special purpose acquisition company, from 2020 to 2021. Mr. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. - Daniel M. Bradbury，自2020年1月起担任董事会执行主席，自2017年3月起担任董事会成员。他于2018年6月至2019年12月担任首席执行官。Bradbury先生是Equillium的联合创始人，并于2017年3月至2018年6月担任总裁。他是BioBrit， LLC（生命科学咨询和投资公司）的创始人和管理成员（2012年9月以来）。2007年3月至2012年8月Amylin被百时美施贵宝公司（Bristol-Myers Squibb company）收购，他担任Amylin Pharmaceuticals， Inc.（一家上市的生物制药公司）的总裁、首席执行官和董事。Bradbury先生自2019年7月起担任Castle Biosciences， Inc 。的董事会成员，他还担任薪酬委员会成员和董事会主席。他自2019年1月起担任Biocon Biologics Ltd.的董事会成员，并担任审计委员会成员。他自2024年3月起担任Vivani Medical， Inc.的董事会成员，在那里他还担任审计委员会成员。此外，他还担任许多私人公司的董事会成员。他曾担任Intercept Pharmaceuticals， Inc.（一家上市的生物技术公司）的董事会成员（从2016年到2023年）；Biocon Ltd.，一家上市的生物制药公司，从2013年到2022年；concept Therapeutics Incorporated，一家上市的生物技术公司，从2012年到2019年；Geron Corporation，一家上市的生物技术公司，从2012年到2019年；Illumina, Inc.（一家上市的生物技术公司），从2004年到2017年；Panacea Acquisition Corporation（一家上市的特殊目的收购公司），从2020年到2021年。他持有Nottingham大学的药学学士学位，以及Harrow and Ealing Colleges of Higher Education的管理学文凭。
- Daniel M. Bradbury,has served as the Executive Chairman of Board since January 2020 and has been a member of Board since March 2017. He served as Chief Executive Officer from June 2018 through December 2019. Mr. Bradbury is a co-founder of Equillium and served as President from March 2017 until June 2018. Mr. Bradbury is the founder and has served as the managing member of BioBrit, LLC ("BioBrit"), a life science consulting and investment firm, since September 2012. Mr. Bradbury served as President, Chief Executive Officer and a director of Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from March 2007 until Amylin's acquisition by Bristol-Myers Squibb Company in August 2012. Mr. Bradbury has served on the board of directors of Castle Biosciences, Inc since July 2019, where he also serves on the compensation committee and as chairman of the board. He has served on the board of directors of Biocon Biologics Ltd. since January 2019, where he also serves on the audit committee. He has served on the board of directors of Vivani Medical, Inc. since March 2024, where he also serves on the audit committee.Additionally, Mr. Bradbury serves on the boards of many private companies. Mr. Bradbury previously served on the boards of directors of Intercept Pharmaceuticals, Inc., a publicly-held biotechnology company, from 2016 to 2023; Biocon Ltd., a publicly-held biopharmaceutical company, from 2013 to 2022; Corcept Therapeutics Incorporated, a publicly-held biotechnology company, from 2012 to 2019; Geron Corporation, a publicly-held biotechnology company, from 2012 to 2019; Illumina, Inc., a publicly-held biotechnology company, from 2004 to 2017; and Panacea Acquisition Corporation, a publicly-held special purpose acquisition company, from 2020 to 2021. Mr. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
- G. Bradley Cole
-
G. Bradley Cole， 自2009年1月起担任首席运营官；从2004年7月到2011年1月担任首席财务官。之前他从2008年1月起担任运营执行副总裁；2004年6月到2009年1月担任执行副总裁和首席财务官。从2005年2月到2012年7月担任公司秘书。从1997年12月到2004年5月在Guidant Corporation（一家医疗设备公司）担任多个职位，最近的职位包括从2001年1月到2004年5月担任内血管解决方案集团金融和业务发展副总裁。从1994年7月到1997年12月他担任 Endovascular Technologies有限公司（一家医疗设备公司，后来被Guidant Corporation收购）金融副总裁和首席财务官。从1988年12月到1994年2月担任Applied Biosystems Incorporated（一家生命科学系统公司）金融副总裁和首席财务官。他持有 比奥拉大学商业学士学位以及圣何塞州立大学工商管理硕士学位。
G. Bradley Cole has served as a member of our board of directors since December 2018. Since June 2014 Mr. Cole has served as Chief Financial Officer of Genomic Health, Inc., a publicly traded global provider of genomic-based diagnostic tests, where he also served as Chief Operating Officer from January 2009 until March 2018 and as Executive Vice President, Operations from January 2008 until January 2009. Mr. Cole previously held Chief Financial Officer positions at multiple publicly traded companies, including Applied Biosciences, Inc. Mr. Cole holds a B.S. degree in Accounting from Biola University and an MBA from San Jose State University. - G. Bradley Cole， 自2009年1月起担任首席运营官；从2004年7月到2011年1月担任首席财务官。之前他从2008年1月起担任运营执行副总裁；2004年6月到2009年1月担任执行副总裁和首席财务官。从2005年2月到2012年7月担任公司秘书。从1997年12月到2004年5月在Guidant Corporation（一家医疗设备公司）担任多个职位，最近的职位包括从2001年1月到2004年5月担任内血管解决方案集团金融和业务发展副总裁。从1994年7月到1997年12月他担任 Endovascular Technologies有限公司（一家医疗设备公司，后来被Guidant Corporation收购）金融副总裁和首席财务官。从1988年12月到1994年2月担任Applied Biosystems Incorporated（一家生命科学系统公司）金融副总裁和首席财务官。他持有 比奥拉大学商业学士学位以及圣何塞州立大学工商管理硕士学位。
- G. Bradley Cole has served as a member of our board of directors since December 2018. Since June 2014 Mr. Cole has served as Chief Financial Officer of Genomic Health, Inc., a publicly traded global provider of genomic-based diagnostic tests, where he also served as Chief Operating Officer from January 2009 until March 2018 and as Executive Vice President, Operations from January 2008 until January 2009. Mr. Cole previously held Chief Financial Officer positions at multiple publicly traded companies, including Applied Biosciences, Inc. Mr. Cole holds a B.S. degree in Accounting from Biola University and an MBA from San Jose State University.
- Bonnie H. Anderson
-
Bonnie H. Anderson，自2008年2月起担任联合创始人、首席执行官和董事会成员，自2016年12月起担任董事会主席。2013年8月至2017年2月，她还担任总裁。Anderson在2006年4月至2008年1月期间担任独立战略顾问，包括在2007年7月至2008年1月期间担任战略顾问。Anderson女士于2000年9月至2006年3月在生物医学测试仪器系统、测试和用品制造商Beckman Coulter, Inc.担任副总裁。Anderson女士目前担任Castle Biosciences公司的董事会成员以及凯克应用生命科学研究所的名誉受托人。Anderson女士拥有宾夕法尼亚印第安纳大学医学技术学士学位。
Bonnie H. Anderson has served as co-founder, Chief Executive Officer and as a member of board of directors since February 2008 and as the Chairman of board of directors since December 2016. From August 2013 to February 2017 she also served as President.Ms. Anderson was an independent strategic consultant from April 2006 to January 2008 including as a strategic consultant from July 2007 to January 2008. Ms. Anderson was a Vice President at Beckman Coulter, Inc., a manufacturer of biomedical testing instrument systems, tests and supplies, from September 2000 to March 2006. Ms. Anderson currently serves as a member of the board of directors of Castle Biosciences, Inc. and as a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. Ms. Anderson holds a B.S. in Medical Technology from Indiana University of Pennsylvania. - Bonnie H. Anderson，自2008年2月起担任联合创始人、首席执行官和董事会成员，自2016年12月起担任董事会主席。2013年8月至2017年2月，她还担任总裁。Anderson在2006年4月至2008年1月期间担任独立战略顾问，包括在2007年7月至2008年1月期间担任战略顾问。Anderson女士于2000年9月至2006年3月在生物医学测试仪器系统、测试和用品制造商Beckman Coulter, Inc.担任副总裁。Anderson女士目前担任Castle Biosciences公司的董事会成员以及凯克应用生命科学研究所的名誉受托人。Anderson女士拥有宾夕法尼亚印第安纳大学医学技术学士学位。
- Bonnie H. Anderson has served as co-founder, Chief Executive Officer and as a member of board of directors since February 2008 and as the Chairman of board of directors since December 2016. From August 2013 to February 2017 she also served as President.Ms. Anderson was an independent strategic consultant from April 2006 to January 2008 including as a strategic consultant from July 2007 to January 2008. Ms. Anderson was a Vice President at Beckman Coulter, Inc., a manufacturer of biomedical testing instrument systems, tests and supplies, from September 2000 to March 2006. Ms. Anderson currently serves as a member of the board of directors of Castle Biosciences, Inc. and as a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. Ms. Anderson holds a B.S. in Medical Technology from Indiana University of Pennsylvania.
高管简历
中英对照 | 中文 | 英文- Federico A. Monzon
FedericoA.Monzon自2015年11月起担任我们的首席医疗官。2013年9月至2015年10月，Monzon博士担任遗传性疾病遗传诊断提供商Invitae Corporation的肿瘤学医学主任和拉丁美洲医学主任。Monzon博士从2011年10月开始担任贝勒医学院（Baylor College of Medicine）癌症遗传学实验室的分子病理学主任，在那里他还被任命为病理学与免疫学系的副教授。Monzon博士自2013年9月起担任病理学和免疫学部门临床副教授。Monzon博士拥有墨西哥国立自治大学（Universidad Nacional Aut&243；Noma de M&233；Xico）的医学博士学位，并获得美国病理学委员会（American Board of Pathology）的解剖与临床病理学和分子遗传学病理学认证。他在Thomas Jefferson University完成病理学住院医师学位，在University of Pittsburgh完成分子病理学奖学金。
Federico A. Monzon has served as our Chief Medical Officer since November 2015. From September 2013 to October 2015 Dr. Monzon served as Medical Director of Oncology and Medical Director for Latin America at Invitae Corporation, a provider of genetic diagnostics for hereditary disorders. Since October 2011 Dr. Monzon held the position of Director of Molecular Pathology at the Cancer Genetics Laboratory from Baylor College of Medicine, where he also had an academic appointment as Associate Professor in the Department of Pathology & Immunology. Since September 2013 Dr. Monzon has held an academic appointment as Clinical Associate Professor in the Department of Pathology and Immunology. Dr. Monzon holds an M.D. degree from the Universidad Nacional Autónoma de México, and is board certified in Anatomic and Clinical Pathology and Molecular Genetic Pathology by the American Board of Pathology. He completed his Pathology residency at Thomas Jefferson University and his Molecular Pathology fellowship at the University of Pittsburgh.- FedericoA.Monzon自2015年11月起担任我们的首席医疗官。2013年9月至2015年10月，Monzon博士担任遗传性疾病遗传诊断提供商Invitae Corporation的肿瘤学医学主任和拉丁美洲医学主任。Monzon博士从2011年10月开始担任贝勒医学院（Baylor College of Medicine）癌症遗传学实验室的分子病理学主任，在那里他还被任命为病理学与免疫学系的副教授。Monzon博士自2013年9月起担任病理学和免疫学部门临床副教授。Monzon博士拥有墨西哥国立自治大学（Universidad Nacional Aut&243；Noma de M&233；Xico）的医学博士学位，并获得美国病理学委员会（American Board of Pathology）的解剖与临床病理学和分子遗传学病理学认证。他在Thomas Jefferson University完成病理学住院医师学位，在University of Pittsburgh完成分子病理学奖学金。
- Federico A. Monzon has served as our Chief Medical Officer since November 2015. From September 2013 to October 2015 Dr. Monzon served as Medical Director of Oncology and Medical Director for Latin America at Invitae Corporation, a provider of genetic diagnostics for hereditary disorders. Since October 2011 Dr. Monzon held the position of Director of Molecular Pathology at the Cancer Genetics Laboratory from Baylor College of Medicine, where he also had an academic appointment as Associate Professor in the Department of Pathology & Immunology. Since September 2013 Dr. Monzon has held an academic appointment as Clinical Associate Professor in the Department of Pathology and Immunology. Dr. Monzon holds an M.D. degree from the Universidad Nacional Autónoma de México, and is board certified in Anatomic and Clinical Pathology and Molecular Genetic Pathology by the American Board of Pathology. He completed his Pathology residency at Thomas Jefferson University and his Molecular Pathology fellowship at the University of Pittsburgh.
- Bernhard E. Spiess
BernhardE.Spiess自2016年5月起担任我们的首席运营官。1997年4月至2016年4月，斯皮斯在BeckmanCoulter，Inc.担任多个职位，该公司是一家生物医学测试仪器系统、测试和用品制造商，2015年2月至2016年4月，斯皮斯担任Vice President、战略营销、血液病毒和传染病等职位，2015年2月至2016年4月，斯皮斯担任营销Vice President，从2008年4月到2015年2月进行分子诊断。在他的整个职业生涯中，Spiess先生在实验室测试和管理，科学支持，销售，战略和战术营销以及产品和业务管理方面担任责任越来越大的职位。Spiess先生拥有B.App.sc。the Royal Melbourne Institute of Technology医疗技术学位。
Bernhard E. Spiess has served as our Chief Operating Officer since May 2016. From April 1997 to April 2016 Mr. Spiess held various positions with Beckman Coulter, Inc., a manufacturer of biomedical testing instrument systems, tests and supplies, including as Vice President, Strategic Marketing, Blood Virus & Infectious Diseases from February 2015 to April 2016 and as Vice President, Marketing, Molecular Diagnostics from April 2008 to February 2015. Throughout his career, Mr. Spiess has held positions of increasing responsibility in laboratory testing and management, scientific support, sales, strategic and tactical marketing, and product and business management. Mr. Spiess holds a B.App.Sc. degree in Medical Technology from the Royal Melbourne Institute of Technology.- BernhardE.Spiess自2016年5月起担任我们的首席运营官。1997年4月至2016年4月，斯皮斯在BeckmanCoulter，Inc.担任多个职位，该公司是一家生物医学测试仪器系统、测试和用品制造商，2015年2月至2016年4月，斯皮斯担任Vice President、战略营销、血液病毒和传染病等职位，2015年2月至2016年4月，斯皮斯担任营销Vice President，从2008年4月到2015年2月进行分子诊断。在他的整个职业生涯中，Spiess先生在实验室测试和管理，科学支持，销售，战略和战术营销以及产品和业务管理方面担任责任越来越大的职位。Spiess先生拥有B.App.sc。the Royal Melbourne Institute of Technology医疗技术学位。
- Bernhard E. Spiess has served as our Chief Operating Officer since May 2016. From April 1997 to April 2016 Mr. Spiess held various positions with Beckman Coulter, Inc., a manufacturer of biomedical testing instrument systems, tests and supplies, including as Vice President, Strategic Marketing, Blood Virus & Infectious Diseases from February 2015 to April 2016 and as Vice President, Marketing, Molecular Diagnostics from April 2008 to February 2015. Throughout his career, Mr. Spiess has held positions of increasing responsibility in laboratory testing and management, scientific support, sales, strategic and tactical marketing, and product and business management. Mr. Spiess holds a B.App.Sc. degree in Medical Technology from the Royal Melbourne Institute of Technology.
- Frank Stokes
Frank Stokes自2017年12月起担任我们的首席财务官。从2017年1月到2017年12月，斯托克斯先生担任Hammock Pharmaceuticals的首席财务官，该公司是一家专注于女性健康和泌尿外科产品开发和商业化的专业制药公司。从2011年5月至2016年12月，Stokes先生担任Leerink Swann（现为SVB Leerink）的董事总经理。Stokes先生还担任Robert W.Baird&Co.的常务董事。股份有限公司和Wachovia Securities，LLC。在SVB Leerink和Robert W.Baird&Co.任职期间，Stokes先生领导生命科学，工具和诊断部门的投资银行业务，并管理融资和并购交易。Stokes先生拥有北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）的工商管理学士学位以及J.D.和工商管理硕士学位。
Frank Stokes has served as our Chief Financial Officer since December 2017. From January 2017 to December 2017 Mr. Stokes served as Chief Financial Officer of Hammock Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of women’s health and urology products. From May 2011 to December 2016 Mr. Stokes served as a Managing Director of Leerink Swann now SVB Leerink. Mr. Stokes also held positions as a Managing Director at Robert W. Baird & Co. Incorporated and Wachovia Securities, LLC. While at SVB Leerink and Robert W. Baird & Co., Mr. Stokes led life sciences, tools and diagnostics sector investment banking efforts, and managed financings and mergers and acquisitions transactions. Mr. Stokes holds a B.S. degree in Business Administration and J.D. and MBA degrees from the University of North Carolina at Chapel Hill.- Frank Stokes自2017年12月起担任我们的首席财务官。从2017年1月到2017年12月，斯托克斯先生担任Hammock Pharmaceuticals的首席财务官，该公司是一家专注于女性健康和泌尿外科产品开发和商业化的专业制药公司。从2011年5月至2016年12月，Stokes先生担任Leerink Swann（现为SVB Leerink）的董事总经理。Stokes先生还担任Robert W.Baird&Co.的常务董事。股份有限公司和Wachovia Securities，LLC。在SVB Leerink和Robert W.Baird&Co.任职期间，Stokes先生领导生命科学，工具和诊断部门的投资银行业务，并管理融资和并购交易。Stokes先生拥有北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）的工商管理学士学位以及J.D.和工商管理硕士学位。
- Frank Stokes has served as our Chief Financial Officer since December 2017. From January 2017 to December 2017 Mr. Stokes served as Chief Financial Officer of Hammock Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of women’s health and urology products. From May 2011 to December 2016 Mr. Stokes served as a Managing Director of Leerink Swann now SVB Leerink. Mr. Stokes also held positions as a Managing Director at Robert W. Baird & Co. Incorporated and Wachovia Securities, LLC. While at SVB Leerink and Robert W. Baird & Co., Mr. Stokes led life sciences, tools and diagnostics sector investment banking efforts, and managed financings and mergers and acquisitions transactions. Mr. Stokes holds a B.S. degree in Business Administration and J.D. and MBA degrees from the University of North Carolina at Chapel Hill.
- Derek J. Maetzold
DerekJ.Maetzold于2007年9月创立了Castle Biosciences，自成立以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。此前，Maetzold先生曾在Encysive Pharmaceuticals、Schering-PloughCorporation（现为默克公司）、Integrated Communications、Amylin Pharmaceuticals和Sandoz Pharmaceuticals（现为诺华公司的一个部门）担任领导职务。Maetzold先生目前担任Ocular Melanoma Foundation的董事。他为癌症的五种诊断和预后测试的发现、开发和商业化做出了贡献，共同撰写了多个科学出版物，是Castle Biosciences和Encysive Pharmaceuticals多项技术的共同发明人。Maetzold先生拥有乔治梅森大学（George Mason University）的生物学B.S.学位，并完成了卡尔加里大学健康科学中心（University of Calgary Health Sciences Center）的额外课程和加州大学河滨分校（University of California，Riverside）的工商管理硕士课程。
Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President and Chief Executive Officer and as a member of our board of directors since inception. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation now Merck, Integrated Communications, Amylin Pharmaceuticals and Sandoz Pharmaceuticals (now a division of Novartis). Mr. Maetzold currently serves as a director of the Ocular Melanoma Foundation. He has contributed to the discovery, development and commercialization of five diagnostic and prognostic tests in cancers, has co-authored multiple scientific publications and is a co-inventor of a number of technologies at Castle Biosciences and Encysive Pharmaceuticals. Mr. Maetzold holds a B.S. degree in Biology from George Mason University and completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at the University of California, Riverside.- DerekJ.Maetzold于2007年9月创立了Castle Biosciences，自成立以来一直担任我们的总裁兼首席执行官，并担任我们的董事会成员。此前，Maetzold先生曾在Encysive Pharmaceuticals、Schering-PloughCorporation（现为默克公司）、Integrated Communications、Amylin Pharmaceuticals和Sandoz Pharmaceuticals（现为诺华公司的一个部门）担任领导职务。Maetzold先生目前担任Ocular Melanoma Foundation的董事。他为癌症的五种诊断和预后测试的发现、开发和商业化做出了贡献，共同撰写了多个科学出版物，是Castle Biosciences和Encysive Pharmaceuticals多项技术的共同发明人。Maetzold先生拥有乔治梅森大学（George Mason University）的生物学B.S.学位，并完成了卡尔加里大学健康科学中心（University of Calgary Health Sciences Center）的额外课程和加州大学河滨分校（University of California，Riverside）的工商管理硕士课程。
- Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President and Chief Executive Officer and as a member of our board of directors since inception. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation now Merck, Integrated Communications, Amylin Pharmaceuticals and Sandoz Pharmaceuticals (now a division of Novartis). Mr. Maetzold currently serves as a director of the Ocular Melanoma Foundation. He has contributed to the discovery, development and commercialization of five diagnostic and prognostic tests in cancers, has co-authored multiple scientific publications and is a co-inventor of a number of technologies at Castle Biosciences and Encysive Pharmaceuticals. Mr. Maetzold holds a B.S. degree in Biology from George Mason University and completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at the University of California, Riverside.